España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Accolade
ACCD
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$3.60
0
0.00%
Pre-Market: 4:00 PM EDT
Get Report
Comment
Accolade (ACCD) Forecast
News
Earnings
Accolade (ACCD) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Accolade (NASDAQ:ACCD) Stock
Accolade Stock (NASDAQ: ACCD)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, October 11, 2024
Wells Fargo Maintains Equal-Weight on Accolad...
Benzinga Newsdesk
Wednesday, October 09, 2024
Forecasting The Future: 6 Analyst Projections For Accolade
Benzinga Insights
Truist Securities Maintains Buy on Accolade, ...
Benzinga Newsdesk
Canaccord Genuity Maintains Buy on Accolade, ...
Benzinga Newsdesk
Barclays Maintains Equal-Weight on Accolade, ...
Benzinga Newsdesk
Stephens & Co. Maintains Overweight on Accola...
Benzinga Newsdesk
Tuesday, October 08, 2024
Needham Reiterates Buy on Accolade, Maintains...
Benzinga Newsdesk
Accolade's Q2 Boost: Revenue Rises, Losses Shrink, And Profitability Looms
Anusuya Lahiri
Accolade Expects Q3 Revenue Of $104M-$107M Vs...
Benzinga Newsdesk
Accolade Q2 2025 GAAP EPS $(0.30) Beats $(0.4...
Benzinga Newsdesk
Accolade Q2 Sales $106.360M Beat $105.012M Es...
Benzinga Newsdesk
Dow Dips Around 400 Points As Treasury Yields Top 4%: Investor Optimism Declines, But Fear Index Remains In 'Greed' Zone
Avi Kapoor
PepsiCo, MEDIROM Healthcare Technologies And 3 Stocks To Watch Heading Into Tuesday
Avi Kapoor
Monday, October 07, 2024
Accolade shares are trading higher. Needham r...
Benzinga Newsdesk
Uncovering Potential: Accolade's Earnings Preview
Benzinga Insights
Needham Reiterates Buy on Accolade, Maintains...
Benzinga Newsdesk
Friday, October 04, 2024
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
Top Wall Street Forecasters Revamp Accolade Price Expectations Ahead Of Q2 Earnings
Avi Kapoor
Monday, August 12, 2024
Accolade shares are trading higher following ...
Benzinga Newsdesk
Watching Accolade; Shares Spike Higher As Tra...
Benzinga Newsdesk
Friday, June 28, 2024
Guggenheim Maintains Buy on Accolade, Lowers ...
Benzinga Newsdesk
Stifel Maintains Buy on Accolade, Lowers Pric...
Benzinga Newsdesk
Truist Securities Maintains Buy on Accolade, ...
Benzinga Newsdesk
Morgan Stanley Maintains Equal-Weight on Acco...
Benzinga Newsdesk
Barclays Maintains Equal-Weight on Accolade, ...
Benzinga Newsdesk
Apple To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Friday
Avi Kapoor
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Avi Kapoor
Canaccord Genuity Maintains Buy on Accolade, ...
Benzinga Newsdesk
Accolade shares are trading lower after the c...
Benzinga Newsdesk
Needham Maintains Buy on Accolade, Lowers Pri...
Benzinga Newsdesk
Thursday, June 27, 2024
Accolade Stock Tumbles On Q1 Earnings, Weak Guidance: What You Need To Know
Adam Eckert
Accolade Sees Q2 Revenue $104M-$106M Vs $113....
Benzinga Newsdesk
Accolade shares are trading lower. The compan...
Benzinga Newsdesk
Accolade Q1 EPS $(0.35) Beats $(0.48) Estimat...
Benzinga Newsdesk
Monday, June 24, 2024
Needham Reiterates Buy on Accolade, Maintains...
Benzinga Newsdesk
Wednesday, May 08, 2024
Guggenheim Maintains Buy on Accolade, Lowers ...
Benzinga Newsdesk
Tuesday, April 30, 2024
Wells Fargo Maintains Equal-Weight on Accolad...
Benzinga Newsdesk
Friday, April 26, 2024
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Avi Kapoor
Morgan Stanley Maintains Equal-Weight on Acco...
Benzinga Newsdesk
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
Truist Securities Maintains Buy on Accolade, ...
Benzinga Newsdesk
Canaccord Genuity Maintains Buy on Accolade, ...
Benzinga Newsdesk
Barclays Maintains Equal-Weight on Accolade, ...
Benzinga Newsdesk
Needham Maintains Buy on Accolade, Lowers Pri...
Benzinga Newsdesk
Thursday, April 25, 2024
Accolade Sees Q1 Revenue $103M-$106M vs $110....
Benzinga Newsdesk
Accolade Q4 2024 GAAP EPS $(0.10) Beats $(0.1...
Benzinga Newsdesk
Monday, April 22, 2024
Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday
Avi Kapoor
Stifel Maintains Buy on Accolade, Lowers Pric...
Benzinga Newsdesk
Monday, February 26, 2024
Accolade Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch